Press release

Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced four leadership appointments across the organization, including lung disease drug development expert Craig Conoscenti, M.D., FCCP, ATSF, who will serve as senior vice president, clinical development. Dr. Conoscenti brings expertise in both clinical academic practice and pharmaceutical clinical development in the pulmonary field, joining Avalyn from Boehringer Ingelheim where he most recently served as executive director and therapeutic area head, interstitial lung disease clinical development and medical affairs. Avalyn also announced today the appointments of Jim Bishop to senior vice president, business operations; Allison Trucillo, M.D., to vice president, medical affairs; and Rebecca Boone to vice president, clinical operations.

"We are thrilled to expand our leadership team with these key appointments as we continue to strategically scale our organization and prepare for advanced clinical development of our lead programs, AP01 and AP02, for pulmonary fibrosis," said Lyn Baranowski, CEO of Avalyn. "Craig adds to Avalyn's clinical development capabilities with a strong track record in the development and launch of multiple products and indications in the respiratory and ILD space, as we work to bring forward new treatments for life-threatening pulmonary diseases. We are also delighted to welcome Jim, Allison and Rebecca to Avalyn, who each bring with them crucial expertise in respiratory drug development to steer our business operations, medical affairs and clinical operations functions as we prepare for key clinical and business milestones this year and beyond."

Prior to Avalyn, Dr. Conoscenti served for 21 years at Boehringer Ingelheim, holding roles of increasing responsibility within interstitial lung disease (ILD) clinical research. He was a key contributor to the development and launch of oral nintedanib for idiopathic pulmonary fibrosis (IPF), scleroderma associated ILD and the other progressive fibrosing ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Trending

More to read